Literature DB >> 1545657

Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy.

J W Bailet1, E Abemayor, B A Jabour, R A Hawkins, C Ho, P H Ward.   

Abstract

Positron emission tomography (PET) has been shown to be effective in detecting intracranial malignancies based on cerebral glucose metabolism. To evaluate the ability of PET to detect extracranial head and neck neoplasms and cervical metastases, 16 patients with primary squamous cell carcinomas were examined. All patients received preoperative computerized tomography (CT) and magnetic resonance imaging (MRI) scans and underwent PET evaluation using intravenous 18F-2-fluoro-2-deoxy-D-glucose (FDG). Histopathologic analysis compared tumor invasion and positive lymph nodes with findings on MRI, CT, and PET images. All primary tumors were delineated by PET, while MRI and CT failed to detect one superficial tumor involving the anterior tongue. Ten nodes were detected by CT and MRI versus 12 nodes demonstrated by PET. PET is highly effective in detecting head and neck carcinomas as well as metastatic cervical lymph nodes. In addition, PET may be useful in evaluating postsurgery and postradiotherapy patients for recurrent and new primary tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1545657     DOI: 10.1288/00005537-199203000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

1.  Management of high-risk cutaneous squamous cell carcinoma.

Authors:  Lorraine Jennings; Chrysalyne D Schmults
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

Review 2.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

3.  Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas.

Authors:  Maky A Hafidh; Peter D Lacy; Joe P Hughes; George Duffy; Conrad V Timon
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

4.  Effectiveness of positron emission tomography for the detection of melanoma metastases.

Authors:  W D Holder; R L White; J H Zuger; E J Easton; F L Greene
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

6.  Pet-FDG imaging in the clinical evaluation of head and neck cancer.

Authors:  W L Wong; E Chevretton; M McGurk; D Croft
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

7.  [18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods.

Authors:  S Dresel; J Grammerstorff; K Schwenzer; K Brinkbäumer; R Schmid; T Pfluger; K Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

8.  Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer.

Authors:  Anthony Hannah; Andrew M Scott; Henri Tochon-Danguy; J Gordon Chan; Tim Akhurst; Salvatore Berlangieri; David Price; Gerard J Smith; Tony Schelleman; W J McKay; Andrew Sizeland
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

9.  201TL SPECT for evaluating head and neck cancer.

Authors:  S Nagamachi; H Hoshi; S Jinnouchi; T Ohnishi; L G Flores; S Futami; H Nakahara; K Watanabe
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

10.  18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma.

Authors:  Davide Padovani; Claudia Aimoni; Pietro Zucchetta; Alessandro Paluzzi; Antonio Pastore
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.